ライフサイエンスコーパス: drug interaction

1 uble stranded deoxyribonucleic acid (ds-DNA)/drug interaction.

2 n plays an important role in the synergistic drug interaction.

3 h p62 that was associated with a synergistic drug interaction.

4 in drug disposition and as a factor in drug-drug interaction.

5 pore corroborated cationic permeability and drug interaction.

6 to decision-making methods for clinical drug-drug interactions.

7 enal failure, as well as posttransplant drug-drug interactions.

8 dications were used, with no documented drug-drug interactions.

9 d not reveal any clinically significant drug-drug interactions.

10 ues at different percentiles and assess drug-drug interactions.

11 drug metabolism and bioavailability and drug-drug interactions.

12 (SCT) is hindered by adverse events and drug-drug interactions.

13 tolerated drugs with less potential for drug-drug interactions.

14 g response and prediction of unexpected drug-drug interactions.

15 al efficacy, poor tolerability, and numerous drug interactions.

16 mmune modulation and resource modulation, to drug interactions.

17 veled the complexity underlying host-microbe-drug interactions.

18 lar-level investigations into sodium channel-drug interactions.

19 ways, as well as possible NTCP-related viral-drug interactions.

20 se toxic effect profiles, comorbidities, and drug interactions.

21 to predict in vivo pharmacokinetics and drug-drug interactions.

22 ical bioavailability, MDR, and possible food-drug interactions.

23 ional therapy-limiting side effects and drug-drug interactions.

24 leads to it, possibly causing undesired drug-drug interactions.

25 ics useful in assessing clinically important drug interactions.

26 alence classes and, in one case, synergistic drug interactions.

27 dominate drug metabolism and determine drug-drug interactions.

28 xt mining of pharmacokinetics parameters and drug interactions.

29 ds can be useful for predicting unknown drug-drug interactions.

30 tein, which predisposes these agents to many drug interactions.

31 the rate of SVR with manageable toxicity and drug interactions.

32 asses and are involved in many clinical drug-drug interactions.

33 high costs, increased pill burden, and many drug interactions.

34 lore the large combinatorial search space of drug interactions.

35 orted adverse events, contraindications, and drug interactions.

36 es were conducted to evaluate potential drug-drug interactions.

37 proved drug with known side effects and drug-drug interactions.

38 , resulting in a wide range of possible drug-drug interactions.

39 ultidrug therapy increases the risk for drug-drug interactions.

40 cause of concern about potential clopidogrel-drug interactions.

41 th the on- and off-target effects of protein-drug interactions.

42 tabolism characteristics, and propensity for drug interactions.

43 clinically significant pharmacokinetic drug-drug interactions.

44 ignificantly influence therapeutics and drug-drug interactions.

45 trator or victim of clinically relevant drug-drug interactions.

46 -O nearest neighbor contacts present in drug-drug interactions.

47 both molecular biomarkers and potential drug-drug interactions.

48 were predicted to potentially cause clinical drug interactions.

49 ndergo metabolism and cause detrimental drug-drug interactions.

50 risk for a host of clinically relevant drug-drug interactions.

51 potential hematologic toxic effects and drug-drug interactions.

52 in HIV-infected persons is the potential for drug interactions.

53 one-induced hepatotoxicity and clinical drug-drug interactions.

54 tions, they can plausibly modify the protein-drug interactions, affecting selectivity and drug-bindin

55 In addition to highlighting relevant drug-drug interactions, alternative drugs that can be safely

56 Drug interaction analysis, which reports the extent to w

57 pound 3 has a much lower propensity for drug-drug interactions and a reduced estimated human half-lif

58 y, there is great potential for serious drug-drug interactions and adverse drug reactions.

59 The potential for drug-drug interactions and altered pharmacokinetics and pharm

60 nt of the cART can avoid risk of significant drug interactions and development of cART-resistant HIV.

61 eased in patients on effective ART; however, drug interactions and drug interruptions are common.

62 ic insights from nonfitness measures of gene-drug interactions and extend the use of mutation accumul

63 DTG has few drug interactions and is taken without regard to meals.

64 These drugs tend to have fewer significant drug interactions and less severe side effects.

65 dies provide quantitative evidence regarding drug interactions and necessary adjustments in the dose

66 iviral resistance, drug metabolism, and drug-drug interactions and optimization of drug adherence are

67 basis for the CYP3A induction class of drug-drug interactions and provided a high-throughput means f

68 gests that CoQ10 is relatively safe with few drug interactions and side effects.

69 an be a useful tool to study tissue-specific drug interactions and the effects of disease-related ion

70 in drug development owing to potential drug-drug interactions and the variability of 3A4 and 3A5 exp

71 logical consequences leading to adverse drug-drug interactions and toxicity.

72 human proteins, human drug metabolism, drug-drug interaction, and drug-induced liver injury.

73 t quantitative knowledge of pharmacokinetic, drug interaction, and evolutionary processes is essentia

74 Adverse reactions to oral azoles, drug interactions, and azole resistance in Aspergillus s

75 improved ADMET properties, low risk for drug-drug interactions, and desirable pharmacokinetic profile

76 tion to preventing infectious complications, drug interactions, and drug interruptions in this patien

77 Off-target effects, drug-drug interactions, and emerging toxicities should be car

78 ypharmacy are increase in side effects, drug-drug interactions, and its high economic cost.

79 le anticoagulant effects, low propensity for drug interactions, and lower rates of intracranial haemo

80 constant review of the pharmacology, dosing, drug interactions, and monitoring techniques may reduce

81 cts among individuals with HIV co-infection, drug interactions, and other sources of heterogeneity, a

82 sk reduction benefits, adverse effects, drug-drug interactions, and patient preferences.

83 prognosis, excessive toxicities, concomitant drug interactions, and poor efficacy.

84 V), but dosing, a low barrier to resistance, drug interactions, and side-effects restrict their use.

85 e individual drugs, the complexities of drug-drug interactions, and the use of sophisticated molecula

86 of Micromedex defined two precautionary drug-drug interactions, and two medications whose use may be

87 tween tumor subtype, oncogenic drivers, gene-drug interactions, and varying niche requirements for tu

88 inical PK data to inform on the risk of drug-drug interactions; and detailed PD studies to determine

89 lications, particularly atrial fibrillation; drug interactions; and infections.

90 ow toxicity profiles and propensity for drug-drug interactions are a goal for future ARV regimens.

91 Several gene-drug interactions are identified, where the copy number

92 inhibition is lost when residues involved in drug interactions are mutated.

93 Drug interactions are often analyzed in terms of isobolo

94 for bacterial or most viral infections, and drug interactions are particularly problematic.

95 be considered when strong P-gp-mediated drug-drug interactions are present.

96 Gene-gene or gene-drug interactions are typically quantified using fitness

97 nt side effects, including increased risk of drug interactions, are described, and the possibility of

98 We focused on warfarin-drug interactions as the prototype.

99 means to predict the magnitude of P-gp-based drug interactions at the BBB and BPB when only the basel

100 Our data suggest that P-gp-based drug interactions at the human BBB and BPB can be clinic

101 nts and genotoxic drugs, we quantify 76 gene-drug interactions based on both mutation rate and fitnes

102 Critically ill patients are predisposed to drug interactions because of the complexity of the drug

103 nt outcome with the two antidepressants (CRP-drug interaction: beta=3.27, 95% CI=1.65, 4.89).

104 The drug-drug interaction between antiplatelet agents and PPIs at

105 esigned to investigate the absence of a drug-drug interaction between boceprevir and raltegravir, an

106 this study due to a clearly illustrated drug-drug interaction between FA and RIF, which lowered FA le

107 wed by 325 mg aspirin revealed a potent drug-drug interaction between ibuprofen and aspirin and betwe

108 Drug interaction between inhibitors of monoamine oxidase

109 inetic testing did not show evidence of drug-drug interaction between irinotecan and alisertib.

110 It was hypothesized a potential drug-drug interaction between morphine and antiplatelet agent

111 d HIV may raise awareness regarding critical drug interactions between antiepileptic drugs and antire

112 Evidence suggests that there may be drug interactions between antiepileptic drugs and hormon

113 Therefore, potential drug interactions between antiretroviral drugs and HCV d

114 This study examined drug interactions between buprenorphine, a partial opioi

115 ticipated, overlap of toxic effects and drug-drug interactions between chemotherapy and ART may alter

116 is study sought to examine the possible drug-drug interactions between clopidogrel and morphine.

117 Drug-drug interactions between commonly coprescribed medicati

118 dies were performed to investigate potential drug interactions between faldaprevir and the commonly u

119 There are challenges of drug interactions between highly active antiretroviral t

120 Our objective was to identify drug interactions between ledipasvir (LDV) and sofosbuvi

121 n be used to optimize the management of drug-drug interactions between PPIs and erlotinib.

122 ients, it is crucial to understand potential drug interactions between tacrolimus (TAC) and the effec

123 nce on the clinical significance of the drug-drug interactions between the available antiplatelet age

124 A matrix of gene and drug interactions built on NCI-60 data identified that I

125 ughput approach with which to screen protein-drug interactions by MALDI mass spectrometry.

126 These drug-drug interactions can increase the risk of toxicity or d

127 Drug-drug interactions can limit the safety of colchicine for

128 method is interpretable in that it generates drug interaction candidates that are traceable to pharma

129 to predict novel DDIs based on similarity of drug interaction candidates to drugs involved in establi

130 perpetrator or victim of clinically relevant drug interactions-coformulated with the NRTI combination

131 Knowledge about drug-drug interactions commonly arises from preclinical trial

132 ucing cytochrome P450 inhibition driven drug-drug interaction concerns to deliver the desired balance

133 Protein-Drug Interaction Database (PDID) addresses incompletenes

134 ically translatable model to assess the drug-drug interaction (DDI) cardiac risk of current and futur

135 Drug-drug interaction (DDI) is an important topic for public

136 Drug-drug interaction (DDI) is becoming a serious clinical sa

137 Seven separate drug-drug interaction (DDI) studies were performed to elucida

138 While knowledge of potential drug-drug interactions (DDI) is necessary to prevent ADR, the

139 perties and potency; however, potential drug-drug interactions (DDI) were predicted based on CYP 2D6

140 P1B3) can result in clinically relevant drug-drug interactions (DDI).

141 ife longer than 40 h and likely to have drug-drug-interactions (DDI), as 2 is a victim of CYP3A4 inhi

142 bition of MATE1 may result in potential drug-drug interactions (DDIs) and alterations in drug exposur

143 Drug-drug interactions (DDIs) are a common cause of adverse d

144 Drug-drug interactions (DDIs) are a major cause of adverse dr

145 psychiatric adverse effects of DAAs and drug-drug interactions (DDIs) between DAAs and psychiatric me

146 ical methods for prediction of putative drug-drug interactions (DDIs) can guide in vitro testing and

147 Drug-drug interactions (DDIs) can lead to serious and potenti

148 ng antivirals (DAAs), the management of drug-drug interactions (DDIs) has become an important challen

149 Identifying drug-drug interactions (DDIs) is a critical process in drug a

150 Drug-drug interactions (DDIs) may cause serious side-effects

151 ively evaluate their potential to cause drug-drug interactions (DDIs).

152 ples for the use of hBCRP mice to study drug-drug interactions (DDIs).

153 eir insufficient potency, side effects, drug-drug interactions, developing drug-resistance, and narro

154 The four types are adverse drug interactions, drug-target interactions, drug-gene a

155 th HIV because of an increased potential for drug interactions due to competing cytochrome P450 metab

156 dicted to have a low risk for potential drug-drug interactions due to its cytochrome P450 3A4 profile

157 PPARalpha, suggesting the potential for drug-drug interactions due to upregulation of CYP2C8 by PPAR

158 terpretation of the clinical significance of drug interactions during targeted temperature management

159 c clearance and is implicated in deleterious drug interactions (e.g., acetaminophen hepatotoxicity) a

160 and clopidogrel showed marked clinical drug-drug interactions (e.g., with cerivastatin and repaglini

161 ns (vs. placebo) using incidence rates, gene-drug interaction effect estimates and allele frequencies

162 onal strategy to explore pharmacokinetic and drug interaction effects in evolutionary models of cance

163 Group x Drug interaction effects were found in the amygdala (sma

164 ility of the PK-corpus was demonstrated by a drug interaction extraction text mining analysis.

165 We present drug interaction fingerprint analysis as a cheap, sensit

166 tive pharmaceutical ingredients by comparing drug interaction fingerprint similarity metrics such as

167 Therefore, drug interaction fingerprinting may be harnessed to diff

168 lified checkerboard assay to generate unique drug interaction fingerprints of antimicrobial drugs.

169 udied, 29 could be identified based on their drug interaction fingerprints.

170 ented in a searchable web-portal called gene-drug Interaction for survival in cancer (GDISC).

171 summarize the available data regarding drug-drug interactions for direct-acting antiviral agents, th

172 atical model was fit to the data to identify drug interactions for effect.

173 We developed a method to analyze drug interactions for the application of identifying act

174 ing evidence networks built with protein and drug interactions from the STITCH and STRING interaction

175 ategy of extracting lapatinib intermolecular drug interactions from the total PDF x-ray pattern was s

176 eed to avoid hypoglycaemia, weight gain, and drug interactions further complicate the treatment proce

177 To assess potential drug interactions, geometric mean ratios and 90% confide

178 Drug-drug interactions have been demonstrated between bocepre

179 Clinicians concerned about clopidogrel-drug interactions have the option of prescribing either

180 , for example, clearance, toxicity, and drug-drug interactions, have been highlighted.

181 LC) have been established for measuring drug-drug interactions; however, they are low-throughput.

182 clinicians to interactively explore the gene-drug interactions identified in the context of TCGA, and

183 , while crystallographic analyses of protein-drug interactions illuminate the mode of drug action and

184 e is no consistent evidence that clopidogrel-drug interactions impact adverse cardiovascular events.

185 icacy of TKIs through lysosome-mediated drug-drug interaction in addition to the commonly proposed au

186 n DA neuron VMAT vesicles and suggests a new drug interaction in which amphetamine induces CYAM depro

187 The collection of all analyzed gene-drug interactions in 32 cancer types are organized and p

188 modifications of silk further modulated the drug interactions in a controlled fashion.

189 use of data mining to discover unknown drug-drug interactions in cardiovascular medicine.

190 e of multiple medical comorbidities and drug-drug interactions in case of polypharmacy.

191 dren requires consideration of critical drug-drug interactions in coinfected children, as these may s

192 tribution of BEV, but also indicate negative drug interactions in concomitant DDP/PTX treatments, sug

193 , suggested low off-target toxicity and drug-drug interactions in humans.

194 promising tool for understanding tumor cell-drug interactions in patient-derived samples including r

195 DDIs will help clinicians to avoid hazardous drug interactions in their prescriptions and will aid ph

196 Because of contraindications and drug-drug interactions, in 2030, 40% of patients could have c

197 e a high potential to cause the toxicity and drug interactions involving CYP enzymes.

198 The current understanding of drug-drug interactions involving the first-line antituberculo

199 Drug-drug interaction is an important element of modern drug

200 enges in proving that a pharmacodynamic drug-drug interaction is clinically significant.

201 dies, the clinical significance of this drug-drug interaction is mixed.

202 We hypothesized that this drug-drug interaction is reversed by taking erlotinib with th

203 A drug-drug interaction is the suspected cause whereby CYP3A4 i

204 The study of protein-drug interactions is a significant issue for drug develo

205 an CYP2C enzymes in drug metabolism and drug-drug interactions is limited.

206 Meticulous attention to drug-drug interactions is required to avoid toxicity and phar

207 ese patients, including medical comorbidity, drug interactions, lack of capacity, and difficulties in

208 set of action, shorter half-life, fewer drug-drug interactions, lack of need for monitoring, and no n

209 The mSTAT3-drug interaction leads to mitochondrial dysfunction, acc

210 lf-administration in rats, suggesting that a drug interaction may contribute to this phenomenon.

211 graft and patient survival rates, but severe drug interactions may limit the usefulness of this thera

212 These drug-drug interactions may reduce the effectiveness of PI/r a

213 Analyzing drug-drug interactions may unravel previously unknown drug ac

214 results suggest that the likelihood of drug-drug interactions mediated by these transporters is stro

215 olution X-ray structure also reveals a water-drug interaction network.

216 We present a new approach to analyzing drug-drug interaction networks, based on clustering and topol

217 (Drug/Drug Interactions of Aspirin and P2Y12-inhibitors; NCT01

218 efficacy, tolerability, and absence of drug-drug interactions of ledipasvir-sofosbuvir suggest that

219 cular signaling; however, the impact of this drug interaction on stent endothelialization is unknown.

220 ever, the clinical significance of this drug-drug interaction on transplantation outcomes has not bee

221 Changes in transport activity based on drug-drug interactions or genetic variability may therefore i

222 study physiology or pathophysiology, examine drug interactions or toxicities, and engineer cardiac ti

223 erbation by direct myocardial toxicity, drug-drug interactions, or both.

224 t P2Y(1)(2) receptor inhibitor without known drug interactions, or statin and gastro-protective agent

225 s (p=0.004), and 24 (6%) versus six (2%) had drug interactions (p=0.0005).

226 g key terms, drug interaction sentences, and drug interaction pairs.

227 Drug pharmacokinetics parameters, drug interaction parameters, and pharmacogenetics data h

228 ion should be considered when assessing drug-drug interaction potential at the transporter.

229 We describe the clinical pharmacology and drug interaction potential of the DAAs, review the inter

230 nce daily, oral administration with low drug-drug interaction potential starting from NHE1 inhibitor

231 oped PPARalpha-targeted drugs for their drug-drug interaction potential.

232 lights the pharmacologic characteristics and drug-interaction potential of BOC and TPV and provides g

233 implification, anticipation of potential new drug interactions, pregnancy or plans for pregnancy, eli

234 QT interval-prolonging drug-drug interactions (QT-DDIs) may increase the risk of lif

235 e to the absence of a clinically significant drug interaction, raltegravir can be recommended for com

236 results indicative of synergistic anticancer drug interactions rarely translate clinically and that t

237 ues related to intrinsic toxicities and drug-drug interactions remain.

238 s proposed and implemented to tag key terms, drug interaction sentences, and drug interaction pairs.

239 ws for extraction of reproducible novel gene-drug interaction signatures as well as accurate test set

240 Drug-drug interaction studies between ART, DAAs, and opiate s

241 Drug-drug interaction studies show that concomitant treatment

242 tation of previous drug disposition and drug-drug interaction studies where conclusions were drawn as

243 es, in vivo pharmacogenetic studies, in vivo drug interaction studies, and in vitro drug interaction

244 vivo drug interaction studies, and in vitro drug interaction studies.

245 More recently, data from drug-interaction studies and 2 small, phase II clinical

246 s, is hampered by chronic inflammation, drug-drug interactions, suboptimum adherence to drug treatmen

247 Analysis of the enzyme-drug interactions suggests that some hydrogen bonds may

248 viding a novel method to determine ligand or drug interactions targeting GPCRs and other membrane pro

249 serious adverse effects, and had fewer drug-drug interactions than those noted with voriconazole.

250 al expression, a clinically significant drug-drug interaction that modulates opioid analgesic efficac

251 , common genetic polymorphisms, and multiple drug interactions that affect its pharmacodynamics and m

252 lizing enzyme is a common mechanism for drug-drug interactions that can lead to altered kinetics in d

253 utility to identify possible beneficial gene-drug interactions that could improve patient survival an

254 data by providing access to putative protein-drug interactions that cover the entire structural human

255 data and patient survival data to infer gene-drug interactions that impact survival.

256 Our findings suggest a major role for drug-drug interactions that lead to P-glycoprotein inhibition

257 ions for enhancing the understanding of drug-drug interactions that will further facilitate the devel

258 for the design of agents that minimize drug-drug interactions, the development of isoform-specific P

259 platform may enable drug metabolism and drug-drug interactions to be interrogated at a scale that can

260 CYP3A4 inhibition may lead to drug-drug interactions, toxicity, and other adverse effects b

261 peline for identifying disease specific gene-drug interactions using CNV (Copy Number Variation) and

262 nd rat liver and evaluate the potential herb-drug interactions using the cocktail approach.

263 Still, resistance and drug-drug interactions warrant the development of new anti-HI

264 A predicted group by drug interaction was noted in the dorsal medial prefront

265 rnal separation by itself nor the rearing-by-drug interaction was significant for either marker.

266 Our aim was to investigate whether drug-drug interactions were discoverable without prior hypoth

267 Significant insights into enzyme-drug interactions were gained via structure-activity rel

268 , highly regulated, compartmentalized kinase-drug interactions were maintained.

269 ) causes a prominent class of dangerous drug-drug interactions wherein one drug accelerates the metab

270 fen, naproxen, and celecoxib-to cause a drug-drug interaction with aspirin in vivo by measuring the t

271 drug hypersensitivity is the end result of a drug interaction with certain HLA molecules and TCRs, th

272 of a clinically significant P-gp-based drug-drug interaction with lenalidomide.

273 Mechanisms of drug interaction with the dendrimer were investigated by

274 affinity for Tyr residues influencing steric drug interaction with the primary Phe residue of the bin

275 ficiency virus (HIV) has been limited due to drug interactions with antiretroviral therapies (ARTs) a

276 by clinically significant toxic effects and drug interactions with antiretroviral therapy.

277 Protein-drug interactions with both GP1 and GP2 are predominatel

278 Further studies in treatment issues and drug-drug interactions with cervical cancer treatments in the

279 tools can successfully describe metal-based drug interactions with DNA.

280 Providers must address drug-drug interactions with EBR/GZR and monitor for changes i

281 d selectivity were manipulated by optimizing drug interactions with enzyme binding pockets, while var

282 The quad does not have drug interactions with H2-receptor antagonists or proton

283 rsensitive responses have been attributed to drug interactions with HLA molecules, peptides presented

284 s are thought to differentially regulate ACT drug interactions with host haem, a product of parasite-

285 er transplantation (LT) patients due to drug-drug interactions with immunosuppression agents.

286 No drug-drug interactions with immunosuppressive drugs were repo

287 It does have substantial drug interactions with medications that are metabolized

288 ronic hepatitis C genotype 1 infection, drug-drug interactions with multiple medications being induct

289 screening drug candidates for potential drug-drug interactions with OATP1B1 and OATP1B3.

290 hematologic side effects and appears to lack drug interactions with selective serotonin reuptake inhi

291 ly R507 showed highly beneficial synergistic drug interactions with Tac.

292 ding the efficacy, safety, and potential for drug interactions with telaprevir and boceprevir had not

293 regimens exhibited no clinically meaningful drug interactions with the 3D regimen.

294 d it is widely accepted that the kinetics of drug interactions with the channel are a critical compon

295 V and provides guidance on the management of drug interactions with these agents.

296 erplay in BSEP as a basis for exploration of drug interactions with this transporter.

297 tion and appropriate management of potential drug interactions with TPV and BOC is critical for optim

298 rends put patients at increased risk of drug-drug interactions with uncertain gains for quality of ca

299 proteins to bind a drug, occurrence of drug-drug interactions within protein binding sites, enzymati

300 We were able to identify known warfarin-drug interactions without a prior hypothesis using clini